

가 , CAP

가 , (4). AJCC T1 2 cm , T1mic 0.1 cm , T1a 0.1 - 0.5 cm, T1b 0.5 cm - 1 cm, T1c 1 cm - 2 cm . T2 2 cm 5 cm , T3 5 cm , T4 T4a , T4b , T4c T4a T4b , T4 . CAP(College of American Pathologists) (2). 1999 CAP , 가 T category / 가 category 2000 CAP 2 (2). 가 , 가 category category 1 “ 2 가 “ TNM (2). category 2 “ 가 0.5cm 가 c - erbB2, 가 p53 . Category 3 “ , EGFR, 2. TGF category 1, 2 가 20 - 30% CAP 가 78 - 80% 가

Category I

1. 가 가 1 (3). 0.1 cm AJCC 6 TNM (micaroinvasive carcinoma)

Table 1. Tumor Size and Outcome in Breast Carcinoma Patients

Size (cm)	5-year survival (%)		
	% Pos. Ax. Nodes	Node-Neg	Node-Pos.
0.1 - 0.5	28	82	52
0.6 - 1.0	24	72	54
1.1 - 2.0	34	68	39
2.1 - 3.0	43	63	39
3.1 - 4.0	50	61	33
4.1 - 5.0	57	58	26
> 5.0	65	57	21

가 70% pN0(mol +)

가 가 H&E ITC 가
가 가 pN0(i+) Connolly 가
(6).
가 2 0.2 - 2 mm pNmi 가
(5). AJCC 6
N1 1 - 3 , N2 4 - 9 , N3
10
inetrrenal mammary lymph node , 가
CAP
가 ,
H&E
CAP ,
가 ,
가 가 ,
4.
level 1, II III 가
3.
AJCC 6 (micrometastasis)
ITC(isolated tumor cells)
ITC 가 0.2
mm pN0 , 3
pN0(i+) , PCR (7).
, CAP
2 mm
H&E 가
cytokeratin
ITC
AJCC
6
pNsn

Table 2. Five-year Overall Survival According to the Number of Involved Axillary Lymph Nodes (505 patients)

No. Positive ALNS	Overall Survival
0	82.8
1	80.1
2	64.6
3	70
4	47.1
4 - 6	54.1
7 - 12	50
0	82.8
1 - 3	73
=> 4	45.7
=> 13	28.4

가
(ER), (PR) . ER PR
77%
ER PR 27%, ER
PR 46%
가 가 (14).
(15).
가
CAP
Allred
가
(2).

Category II

1. c-erbB2 (Her2- neu)
가
her - 2 가
가 (16).
CAP her - 2 cat -
egory I
. HER2/neu /
, tyrosine kinase
20 - 30 - % HER2/neu
Herceptin
HER2/neu
FDA

HER2/neu
. HER2/neu
mRNA 가 가
FISH(Fluorescence in situ hybridization) (16, 17).




Fig. 1. The diagram of scoring system of mitotic figures according to the field diameter of microscopes.




Fig. 2. The diagram of semiquantitative scoring system of hormone receptors by Allred.

2.

CD31, CD34, - VIII related antigen

가
가
(25).

3.

Epidermal growth factor receptor, transform-
ing growth factor - α , bcl - 2, pS2, Cathepsin D

(26 - 28).

가

가

extensive intraductal com -
ponent(EIC) (29, 30). EIC
25%

. EIC

EIC

가

가

가 가

, 가

1. Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. *J Natl Cancer Inst Monogr* 2001; 30:5-15
2. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. *Arch Pathol Lab Med* 2000; 124:966-978
3. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. *Cancer* 1989; 63:181-187
4. Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual. New York: Springer-Verlag, 2002

5. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. *Cancer* 1983;52:1551-1557
6. Connolly JL. Changes and problematic areas in interpretation of the AJCC Cancer Staging Manual, 6th Edition, for breast cancer. *Arch Pathol Lab Med* 2006; 130:287-291
7. Krag DN, Julian TB, Harlow SP, et al. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinel lymph node dissection: a description of the trial. *Ann Surg Oncol* 2004; 11:208S-210S
8. Greenough RB. Varying degrees of malignancy in cancer of the breast. *J Cancer Res* 1925; 1925:452-463
9. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. *Br J Cancer* 1957; 11:359-377
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology* 1991; 19:403-410
11. Ellis IO GM, Broughton N, Locker A, Blamey RW, Elston CW. Pathologic prognostic factors in breast cancer. II. Histologic type. Relationship with survival in a large study with long-term follow-up. *Histopathology* 1992; 20:479-489
12. Aaltomaa S, Lipponen P, Eskelinen M, et al. Mitotic indexes as prognostic predictors in female breast cancer. *J Cancer Res Clin Oncol* 1992; 118:75-81
13. Pichon MF, Broet P, Magdelenat H, et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. *Br J Cancer* 1996; 73:1545-1551
14. F S. Prognostic value of ER and PR in primary infiltrating breast cancer. A sequential multivariate analysis of 1262 patients. *Eur J Cancer Clin Oncol* 1989;25
15. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol* 1999; 17:1474-1481
16. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. *J Clin Oncol* 1998; 16:462-469
17. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. *J Clin Oncol* 1997; 15:2894-2904
18. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. *Int J Cancer* 1996; 69
19. Saigo PE, Rosen PP. The application of immunohistochemical stains to identify endothelial-lined channels in mammary carcinoma. *Cancer* 1987;59:51-54
20. Lee AK, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. *J Clin Oncol* 1990; 8:1457-1465
21. Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. *Clin Cancer Res* 1996;2:585-592
22. Haerslev T, Jacobsen GK, Zedeler K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. *Breast Cancer Res Treat* 1996; 37:101-113

23. Bryant J, Fisher B, Gunduz N, Costantino JP, Emir B. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. *Breast Cancer Res Treat* 1998;51:239-253
24. Balslev I, Christensen IJ, Rasmussen BB, et al. Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer. *Int J Cancer* 1994;56:16-25
25. Arora R JK, Nijhawan R. Angiogenesis as an independent prognostic indicator in node-negative breast cancer. *Anal Quant Cytol Histol* 2002;24:228-233
26. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. *J Natl Cancer Inst* 1994;86:499-504
27. Salomon DS, Bianco C, De Santis M. Declining semen quality: can the past inform the present? *Bioessays* 1999; 21:614-621
28. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. *Br J Cancer* 1999; 79:300-307
29. Veronesi U, Luini A, Galimberti V, Zurrida S. Conservation approaches for the management of stage I/II carcinoma of the breast: Milan Cancer Institute trials. *World J Surg* 1994; 18:70-75
30. Heimann R, Powers C, Halpem HJ, et al. Breast preservation in stage I and II carcinoma of the breast. The University of Chicago experience. *Cancer* 1996; 78:1722-1730